Form 4: Madrigal Pharmaceuticals Director Acquires Stock

Jacqualyn A. Fouse, a Director at Madrigal Pharmaceuticals, Inc., acquired 454 shares of common stock and was granted stock options for 766 shares.

Summary

• Director Jacqualyn A. Fouse acquired 454 shares of Madrigal Pharmaceuticals, Inc. common stock on June 17, 2026.
• The acquisition of common stock was valued at $0, indicating it was likely a grant or award.
• Fouse also received a stock option grant for 766 shares of common stock with an exercise price of $499.86.
• This option vests fully on June 17, 2027, or at the Issuer's 2027 annual meeting, whichever comes first, provided Fouse remains in service.
• Following these transactions, Fouse beneficially owns 1,551 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider transactions (stock acquisition and option grant) without providing new financial or strategic information that would significantly alter the investment outlook.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• Granting of stock options aligns management incentives with shareholder value creation.
• The vesting schedule for the stock option encourages long-term commitment from the director.

Negatives

• The filing does not provide financial performance data, making it difficult to assess the company's overall health.
• The acquisition of common stock was at a $0 price, suggesting it was an award rather than an open market purchase, which provides less insight into market sentiment.

Risks

• The stock option grant has a specific vesting condition tied to continued service, implying a risk of forfeiture if service is not maintained.
• The exercise price of the stock option ($499.86) is high, suggesting that the stock price would need to increase significantly for the option to be profitable.

Future Outlook

The stock option granted to Jacqualyn A. Fouse vests on June 17, 2027, or the date of the Issuer's 2027 annual meeting, whichever is earlier, provided she continues in service. This indicates a forward-looking incentive tied to continued employment and potential future stock performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as director stock acquisitions and option grants, are common in the pharmaceutical industry as companies use equity-based compensation to attract and retain talent and align executive interests with long-term company growth and shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of stock by a director may be viewed positively, suggesting insider confidence, but the $0 acquisition price indicates it was an award, not a market purchase.
• Employees: The stock option grant structure aligns with common employee and executive incentive programs, potentially motivating continued service.
• Management: The grant of stock options serves as a retention tool and an incentive for management to drive stock performance.

Next Steps

• The stock option granted will vest on June 17, 2027, or the date of the Issuer's 2027 annual meeting, contingent on continued service.
• Further insider transactions by Jacqualyn A. Fouse or other company insiders may be reported in future SEC filings.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director, SEC Filing, Beneficial Ownership